Technical Analysis for IONS - Ionis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 55.26 -0.95% -0.53
IONS closed down 0.95 percent on Monday, October 21, 2019, on 1.28 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Nov 4

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IONS trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -0.95%
Lower Bollinger Band Walk Weakness -0.95%
Stochastic Reached Oversold Weakness -0.95%

Older signals for IONS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. It markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. The company's drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. It is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. In addition, the company is developing products, which are Phase II clinical trials include IONIS-DMPK-2.5Rx for myotonic dystrophy type 1; IONIS-HTTR for huntington's disease; ATL1103 for acromegaly; IONIS-FXIRx (BAY 2306001) for clotting disorders; IONIS-APO(a)-LRx for high Lp; IONIS-ANGPTL3-LRx for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5Rx (AZD9150) for cancers; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; and RG-101 for hepatitis C virus infection, as well as products for the treatment of diabetes and obesity. Further, its products in Phase I clinical include IONIS-GCCRRx for cushing's syndrome; IONIS-PKKRx for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5Rx (AZD5312) for prostate cancer; IONIS-HBVRx for hepatitis B virus infection; IONIS-GSK4-LRx for ocular disease; and IONIS-DGAT2Rx for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Cancer Organ Systems Diabetes Cancers Drug Discovery Prostate Cancer Disorders Multiple Sclerosis Obesity Genetics Neurological Disorders Huntington's Disease Spinal Muscular Atrophy Treatment Of Diabetes Orphan Drugs Acromegaly Cushing's Syndrome Hepatitis C Virus Infection Hereditary Angioedema Therapeutic Gene Modulation Antisense RNA Familial Amyloid Polyneuropathy Severe And Rare Diseases Familial Chylomicronemia Syndrome Familial Partial Lipodystrophy Homozygous Familial Hypercholesterolemia Myotonic Dystrophy TTR Amyloidosis
Is IONS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 86.58
52 Week Low 45.48
Average Volume 963,756
200-Day Moving Average 66.4112
50-Day Moving Average 62.9438
20-Day Moving Average 59.2825
10-Day Moving Average 59.249
Average True Range 2.2332
ADX 22.48
+DI 16.5169
-DI 31.6676
Chandelier Exit (Long, 3 ATRs ) 57.5704
Chandelier Exit (Short, 3 ATRs ) 61.1096
Upper Bollinger Band 63.5512
Lower Bollinger Band 55.0138
Percent B (%b) 0.03
BandWidth 14.401215
MACD Line -1.5132
MACD Signal Line -1.1802
MACD Histogram -0.3331
Fundamentals Value
Market Cap 6.87 Billion
Num Shares 124 Million
EPS 0.21
Price-to-Earnings (P/E) Ratio 263.14
Price-to-Sales 13.91
Price-to-Book 31.29
PEG Ratio -7.79
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 57.83
Resistance 3 (R3) 57.83 56.97 57.40
Resistance 2 (R2) 56.97 56.32 56.97 57.26
Resistance 1 (R1) 56.12 55.92 55.69 56.12 57.11
Pivot Point 55.26 55.26 55.05 55.26 55.26
Support 1 (S1) 54.41 54.61 53.98 54.40 53.41
Support 2 (S2) 53.55 54.21 53.55 53.26
Support 3 (S3) 52.70 53.55 53.12
Support 4 (S4) 52.69